HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases

被引：10

作者：

Liu, Xiaoyan ^{[1
]}

Wang, Xiaoling ^{[1
]}

Wang, Bo ^{[1
]}

Ren, Guoping ^{[1
]}

Ding, Wei ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Pathol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China

来源：

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2016年 / 24卷 / 07期

关键词：

gastric cancer; fluorescence in situ hybridization; HER2/neu; PROTEIN EXPRESSION; BREAST-CANCER; NEU ONCOGENE; RECEPTOR; ADENOCARCINOMA; VALIDATION; PROGNOSIS; CARCINOMA; PATTERNS;

D O I：

10.1097/PAI.0000000000000219

中图分类号：

R602 [外科病理学、解剖学]; R32 [人体形态学];

学科分类号：

100101 ;

摘要：

Objective: To determine the frequency of HER2/neu amplification and the relationship between HER2/neu expression and clinicopathologic features in gastric cancers scored immunohistochemistry (IHC) 2+. Methods: A total of 122 gastric cancer cases scored IHC 2+ were retrospectively analyzed for HER2 amplification by fluorescence in situ hybridization (FISH). The correlation between HER2/neu expression and clinicopathologic features was analyzed. Results: HER2/neu gene was amplified in 17 out of the 122 gastric cancer samples. The concordance rate between IHC and FISH was 13.9%. HER2/neu status was correlated with the age of patients (P<0.05). Polysomy of CEP17 was demonstrated in 46 cases, 11 of which (23.91%) were amplified for HER2/neu. Within the subgroups, a correlation between CEP17 polysomy and the depth of invasion was observed (P<0.05). Conclusions: The results highlight the necessity of FISH test for further categorization when gastric cancer cases are scored 2+ by IHC. The value of HER2/neu for a potential role as a negative prognostic factor in the equivocal gastric cancer cases is limited.

引用

页码：459 / 464

页数：6

共 25 条

[1]

Bang YJ, 2010, LANCET, V376, P1302

[2] TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].